Patents for Our Five Top Selling Products | Amgen

Patents for Our Five Top Selling Products1

This disclosure is intended to simplify the activity of locating our patents documenting the scientific breakthroughs that these products represent. The patent table below lists patents currently in force that appear on the product virtual label, are cited in the 2022 10-K report, are cited in the Orange Book, and/or are cited in the Purple Book for our five top selling products1:

Product 

Proprietary/(Proper) Name

Patent Number

General Subject Matter

1. Enbrel® (etanercept) 

U.S. 11,491,223;
U.S. 10,307,483

Formulations and methods of preparing formulations

U.S. 8,063,182

Fusion protein and pharmaceutical compositions

U.S. 8,163,522

DNA encoding fusion protein and methods of making fusion protein

2. Prolia® (denosumab)*


3. XGEVA® (denosumab)*

 

 

U.S. 7,364,736

RANKL antibodies, including sequences

U.S. 7,427,659

Process for purifying proteins in a hydrophobic interaction chromatography flow-through fraction 

U.S. 7,928,205

Methods for refolding of recombinant antibodies

U.S. 8,058,418

Nucleic acids encoding RANKL antibodies and methods of producing RANKL antibodies 

U.S. 9,012,178

Methods of culturing mammalian cells to express protein in a serum free medium

U.S. 9,133,493

Methods of culturing mammalian cells 

U.S. 9,228,168

Methods of stabilizing feed media 

U.S. 9,320,816

Methods of treating cell culture media 

U.S. 9,328,134

Methods of making proteins with modified glycosylation profile

U.S. 9,359,435

Methods of modulating glycoform content 

U.S. 9,388,447

Independent tyrosine feed 

U.S. 9,481,901

Methods of influencing high mannose glycoform content

U.S. 10,167,492

Methods of influencing fucosylated glycan content

U.S. 10,513,723

Methods of influencing high mannose glycoform content

U.S. 10,583,397

Systems and methods to control filtration

U.S. 10,822,630

Methods of influencing fucosylated glycan content

U.S. 10,894,972

Methods of influencing high mannose glycoform content 

U.S. 11,077,404

Systems and methods to control filtration

U.S. 11,098,079

Methods of using a charged depth filter

U.S. 11,130,980

Methods of regulating high mannose glycoform content 

U.S. 11,254,963

Methods of influencing high mannose glycoform content

U.S. 11,299,760

Methods of regulating high mannose glycoform content 

U.S. 11,434,514

Methods of influencing high mannose glycoform content 

U.S. 11,459,595

Methods for increasing mannose content of recombinant proteins

EP 1 409 016

RANKL antibodies, including sequences 

4. Otezla® (apremilast)

U.S. 7,427,638

Composition and compound

U.S. 7,893,101

Crystalline form

U.S. 9,872,854; 
U.S. 10,092,541

Methods of treatment

EP 2 962 690

Compositions, compounds and methods of treatment

5. Aranesp® (darbepoetin alfa)

U.S. 7,217,689

Glycosylation analogs of erythropoietin proteins

*Prolia and XGEVA are brand names for denosumab, but differ in indications.


1. Based on our publicly reported sales as disclosed in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 9, 2023.  We are providing this information as of September 1, 2023.